|Awarded On||August 19, 2020|
|Title||Arming an Oncolytic Herpes Simplex Virus to "BiTE" Tumor Cells|
|Award Mechanism||Individual Investigator|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Xiaoliu Zhang|
|Cancer Sites||All Sites|
*Pending contract negotiation
US Food and Drug Administration (FDA) has recently approved a type I herpes simplex virus (HSV-1) based oncolytic virus, T-VEC (Imlygic), for treatment of melanoma. This is the first FDA approval for virotherapy, a new type of cancer treatment that is based a pragmatic therapeutic principle - purposefully modifying a virus so that it can selectively kill malignant cells. My laboratory has employed a novel mechanism to create a HSV-2-based oncolytic virus, the first of this kind (all other oncolytic HSVs, including, T-VEC are constructed from HSV-1). Designated FusOn-H2, it showed potent activity against many tumor types, including breast cancer, pancreatic cancer, ovarian cancer and prostate...